The FDA approved Onswik (insulin efsitora alfa) on September 24, 2026, clearing Eli Lilly's once-weekly basal insulin for adults with type 2 diabetes. The approval gives patients an alternative to daily basal insulin injections and sets up a direct rivalry with Novo Nordisk's Awiqli, the once-weekly insulin that reached the U.S. market in March 2026.
What Onswik Is
Insulin efsitora alfa is a novel basal insulin engineered for an extended half-life, allowing once-weekly dosing instead of the once- or twice-daily injections required by older basal insulins like glargine and degludec. Like other basal insulins, it is a peptide hormone analog designed to provide steady background insulin coverage between meals and overnight, rather than covering the blood sugar spikes that come with eating.
What the Trials Showed
Eli Lilly evaluated Onswik in the Phase 3 QWINT clinical trial program, which enrolled roughly 3,400 adults with type 2 diabetes. Across the program, once-weekly Onswik was shown to be non-inferior to standard daily basal insulins. In the QWINT-2 trial specifically, Onswik reduced A1C by 1.34 percentage points, compared with 1.26 percentage points for insulin degludec (Tresiba), a difference the FDA and Lilly consider clinically comparable. Lilly has said the once-weekly schedule could mean more than 300 fewer injections per year for patients switching from a daily basal insulin.
Regulatory Status and Safety
Onswik is FDA-approved specifically for adults with type 2 diabetes; its label states it should not be used in people with type 1 diabetes, where the risk of dangerously low blood sugar (hypoglycemia) is higher and dosing precision needs differ. As with any basal insulin, hypoglycemia is the primary safety concern, and patients starting or switching insulin regimens should be monitored closely, especially during the transition from a daily to a weekly schedule.
Competitive Context
Onswik enters a market Novo Nordisk already opened with Awiqli, approved in the U.S. in March 2026 as the first once-weekly basal insulin. The two products compete on similar ground: both aim to reduce injection burden for people with type 2 diabetes, and both will likely be positioned against each other on cost, formulary access, and the exact durability of glucose control across a full week. Coming so soon after Awiqli, Onswik's approval keeps the pressure on both companies to demonstrate real-world adherence benefits, not just trial non-inferiority. The rivalry mirrors the broader pattern already playing out between the two companies' GLP-1 franchises, where competing approvals have arrived within months of each other across multiple drug classes this year.
Talk to Your Doctor
Switching basal insulin regimens, especially moving from a daily to a weekly dosing schedule, changes how blood sugar needs to be monitored during the transition. Anyone currently on insulin therapy should discuss any change with their prescribing physician rather than adjusting a diabetes regimen independently.
The Bottom Line
Onswik's approval is a genuine regulatory milestone: a second once-weekly basal insulin now has FDA clearance, giving patients and prescribers more choice in a drug class that hadn't changed its basic dosing rhythm in decades. Whether it meaningfully outperforms Awiqli in practice, rather than just on paper, will depend on real-world data that hasn't been generated yet.